As competence grows, biopharmaceuticals are searching for ways to present their specific psychedelic substance-assisted therapies in a way that might differentiate them from their competitors while maintaining safety and efficiency standards.

In this sense, Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech firm aiming to tackle addictions, has signed a development agreement with Catalent, a global company aiding biopharma, cell, gene, and consumer health partners to optimize the development, launch and supply of treatments across multiple modalities

The agreement is set to investigate a market-ready proprietary formulation and optimized delivery route for Awakn’s MDMA using Catalent's Zydis …

Full story available on Benzinga.com